Andrew J. Greenfield - Dec 16, 2022 Form 4 Insider Report for ABIOMED INC (NASD)

Signature
/s/ Marc A. Began (by power of attorney)
Stock symbol
NASD
Transactions as of
Dec 16, 2022
Transactions value $
$0
Form type
4
Date filed
12/20/2022, 03:05 PM
Previous filing
Nov 8, 2022
Next filing
Dec 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $.01 par value Award $0 +14 +0.09% $0.00 16K Dec 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (right to buy) 5K Dec 16, 2022 Common Stock 0 $99.62 Direct F2, F3
holding NASD Stock Option (right to buy) 6.5K Dec 16, 2022 Common Stock 0 $134.51 Direct F2, F3
holding NASD Stock Option (right to buy) 4K Dec 16, 2022 Common Stock 0 $381.97 Direct F2, F3
holding NASD Stock Option (right to buy) 7K Dec 16, 2022 Common Stock 0 $266.39 Direct F2, F3
holding NASD Stock Option (right to buy) 4.9K Dec 16, 2022 Common Stock 0 $223.90 Direct F2, F3
holding NASD Stock Option (right to buy) 2.87K Dec 16, 2022 Common Stock 0 $283.88 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c)
F2 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F3 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.